Mithat Buyukcelik

Mithat Buyukcelik

Auto-generated profile, based on publicly available information

Mithat Buyukcelik

Department of Pediatric Nephrology, Gaziantep University Faculty of Medicine, Gaziantep, Türkiye

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2021 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
ABAyse Balat
Ayse Balat
BKBeltinge Demircioglu Kilic
Beltinge Demircioglu Kilic
BABagdagul Aksu
Bagdagul Aksu
MKMehtap Akbalik Kara
Mehtap Akbalik Kara
MBMithat Buyukcelik
Mithat Buyukcelik
FSFerah Sonmez
Ferah Sonmez

1 March 2022 in Brazilian Journal of Nephrology
Verified
Journal Article
Open access
MKMehtap Akbalik Kara
Mehtap Akbalik Kara
BKBeltinge Demircioğlu Kiliç
Beltinge Demircioğlu Kiliç
MBMithat Büyükçelik
Mithat Büyükçelik
ABAyşe Balat
Ayşe Balat
Introduction Henoch-Schönlein purpura nephritis (HSN) is defined as Henoch-Schönlein purpura with kidney involvement, including hematuria and/or proteinuria. The aim of this study was to evaluate the data of HSN patients who underwent renal biopsy, and compare the main clinical and laboratory parameters that may affect renal biopsy findings, treatment protocols, and short- and long-term outcome of those patients. Methods Biopsies performed in 72 HSN patients between January 2007 to January 2017 were retrospectively evaluated. They were divided into two groups according to renal biopsy classification of the International Study of Kidney Disease in Children. Renal outcome, clinical and laboratory parameters, treatment protocols, and outcome were compared between groups. Short- and long-term follow-up of patients were evaluated. Results Of 72 patients, 47 were male (65.3%) and 44 (61.1%) were ≤10 years of age. Neutrophil-lymphocyte ratio was found higher in patients with scrotal involvement (p=0.042). Short-term unfavorable outcome was significantly higher in patients with scrotal involvement (p=0.038). Patients with hypertension and decreased creatinine clearance were found to have more unfavorable outcomes in long-term follow-up (p=0.029, p=0.040). Conclusion Cyclosporin-A and cyclophosphamide could be effective in steroid unresponsive HSN patients. Patients with scrotal involvement, decreased creatinine clearance, and hypertension should be closely monitored for sequelae of HSN.

20 August 2020 in Harran Üniversitesi Tıp Fakültesi Dergisi
Verified
Journal Article
Closed access
PDF file
MKMehtap Akbalik Kara
Mehtap Akbalik Kara
BKBeltinge Demi̇rci̇oğlu Kiliç
Beltinge Demi̇rci̇oğlu Kiliç
MBM Buyukceli̇k
M Buyukceli̇k
ABAyşe BALAT
Ayşe BALAT
Amaç: Henoch-Schönlein purpurası (HSP) tanısı ile izlenen hastaların demografik, klinik ve laboratuvar özelliklerini değerlendirmek ve böbrek tutulumu riski açısından karşılaştırmak Materyal ve metod: Ocak 2015-Ocak 2017 tarihleri arasında hastanemiz çocuk nefroloji-romatoloji polikliniğinde HSP tanısı konup en az 1 yıl süre ile izlenen hastaların dosyaları gözden geçirildi. Demografik veriler, öykü, tanı yaşı, fizik muayene, laboratuvar tetkikleri, organ tutulumları, böbrek biyopsileri, tüm tedavi rejimleri ve izlemleri değerlendirildi. Bulgular: Çalışmamızda 2 yıllık süre içinde 57’si erkek (% 48.3) 61’i kız (% 51.7) toplam 118 hasta vardı. Hastaların yaş ortalaması 7.9 ± 2.81, kız: erkek oranı 1: 0.93 idi. 10 yaş altında 98 hasta (% 83.1) varken, 10 yaş üzeri hasta sayısı 20 (% 16.9) idi. Hastalarda yaş, cinsiyet, hastalık tekrarı, eklem tutulumu yeri ve süresi, döküntünün yeri ve süresi, gastrointestinal tutulum, testis tutulumu, laboratuar parametreleri ile böbrek tutulumu karşılaştırıldığında anlamlı bir ilişki saptanmadı. Sonuç: İki yıllık süre içinde HSP tanısı ile izlediğimiz hastaları geriye dönük olarak değerlendirdiğimizde böbrek tutulumu açısından risk faktörlerine baktığımızda anlamlı bir faktör tespit edemedik. Aslında bu durum bize tüm HSP hastalarının dikkatli bir biçimde renal tutulum açısından takip edilmesi gerektiğini düşündürmektedir. Abstract Background: To evaluate the demographic, clinical and laboratory characteristics of patients with Henoch-Schönlein purpura (HSP) and compare the risk of renal involvement Materials and Methods: The files of the patients who were diagnosed as HSP in the pediatric nephrology-rheumatology clinic of our hospital between January 2015 and January 2017 and followed for at least 1 year were reviewed. Demographic data, history, age at diagnosis, physical examination, laboratory tests, organ involvement, renal biopsies, all treatment regimens and follow-up were evaluated. Results: There were 118 patients 57 male (48.3%), 61 female (51.7%) in a 2-year period. The mean age of the patients was 7.9 ± 2.81 and the female: male ratio was 1: 0.93. While there were 98 patients (83.1%) under 10 years of age, the number of patients over 10 years of age was 20 (16.9%). There was no significant relationship between age, sex, recurrence of disease, location and duration of joint involvement, location and duration of rash, gastrointestinal involvement, testicular involvement, laboratory parameters and renal involvement. Conclusion: When we retrospectively evaluated the patients whom were followed up with the diagnosis of HSP over a two-year period, we did not find any significant factor in the risk factors for renal involvement. In fact, this suggests that all HSP patients should be carefully monitored for renal involvement.

2 January 2026 in Balkan Medical Journal
Verified
Journal Article
Open access
MKMehtap Akbalık Kara
Mehtap Akbalık Kara
BKBeltinge Demircioğlu Kılıç
Beltinge Demircioğlu Kılıç
MBMithat Büyükçelik
Mithat Büyükçelik
ABAyşe Balat
Ayşe Balat

19 October 2024 in Iranian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
ADAlper Dogan
Alper Dogan
ABAyse Balat
Ayse Balat
BKBeltinge Demircioglu Kilic
Beltinge Demircioglu Kilic
MKMehtap Akbalık Kara
Mehtap Akbalık Kara
MBMithat Buyukcelik
Mithat Buyukcelik
Background: Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disorder commonly found in populations from the Mediterranean region, including Turks, Armenians, Arabs, and Jews. It is characterized by recurrent episodes of fever and inflammation, primarily affecting the peritoneum, pleura, and joints. Familial Mediterranean fever is caused by mutations in the MEFV gene, which encodes pyrin, a protein that regulates the inflammatory response. The most common mutations associated with FMF are M694V, M680I, and V726A. These mutations lead to the overproduction of interleukin-1β (IL-1β), triggering the inflammatory episodes that are the hallmark of the disease. Objectives: This study aims to explore the clinical implications of MEFV gene mutations in a cohort of patients diagnosed with FMF and treated with colchicine. The primary objective is to determine the frequency of various MEFV mutations in the patient cohort and examine their association with clinical presentations, such as symptom severity and response to treatment. Methods: A retrospective cohort of 302 patients diagnosed with FMF and undergoing colchicine treatment was examined. Demographic data, clinical symptoms, and genetic mutations were systematically collected and analyzed. Mutation analysis focused on identifying the most common MEFV variants and their potential influence on clinical outcomes. Consanguinity and family history were also considered for their role in FMF genetic predisposition. Results: The study included 157 females and 145 males, with a mean age of 142.60 ± 48.04 months at the time of analysis. The average age of diagnosis was 94 ± 42 months, with no significant differences between genders. Abdominal pain was the most common symptom (90.3%), followed by fever (69.0%) and arthralgia (42.3%). Consanguinity was reported in 35.1% of cases, mainly between first-degree cousins, and 24.5% had a family history of FMF. Genetic analysis revealed that the M694V mutation was the most common homozygous mutation (71.4%), followed by the E148Q mutation as the most frequent heterozygous mutation (37.5%). The compound heterozygous mutation M694V/E148Q was found in 20% of cases. A statistically significant association was found between arthritis and homozygous mutations (P = 0.001) as well as with the M694V mutation (P = 0.004). Homozygous M694V mutations were detected in 16.9% of patients. The findings underscore a strong correlation between the M694V mutation and the development of FMF. Despite the efficacy of colchicine in managing symptoms and preventing complications such as amyloidosis, some patients exhibited treatment resistance, particularly those with arthritis. Conclusions: This study highlights the significant role of MEFV gene mutations, particularly M694V, in the pathogenesis of FMF. It underscores the importance of early diagnosis and the potential for personalized treatment based on genetic findings. While the retrospective design of the study presents limitations, such as selection and information bias, the results provide valuable insights into the clinical and genetic dimensions of FMF. Future studies should build on these findings by using prospective designs and investigating the interaction between genetic and environmental factors in FMF. Expanding the scope of genetic analysis could also lead to the discovery of new mutations, enhancing our understanding of this complex disorder.